Summit Therapeutics teams with ECOG-ACRIN on phase II/III ivonescimab trial in biliary tract cancer

SMMT•2026-10-21

Summit Therapeutics partnered with ECOG-ACRIN on a phase II/III trial of ivonescimab for first-line advanced biliary tract cancer. US site activations are expected to begin in the fourth quarter of 2026.

1. Trial design

The registration-enabling EA2251 trial will compare ivonescimab with pembrolizumab or durvalumab, each combined with chemotherapy. Overall survival is the primary endpoint, and US clinical trial site activations are expected to begin in the fourth quarter of 2026.

2. Earlier trial results

Akeso’s China-based phase III HARMONi-GI1 trial previously showed ivonescimab with chemotherapy improved survival over durvalumab with chemotherapy in biliary tract cancer. Detailed results are scheduled for presentation October 25 at the European Society for Medical Oncology 2026 Congress.

Summit Therapeutics teams with ECOG-ACRIN on phase II/III ivonescimab trial in biliary tract cancer

1. Trial design

2. Earlier trial results

Related News

Kroger Co.: Deutsche Bank raises target price to $70 from $68

Gold hits near one-week low on elevated oil prices

SpaceX: TD Cowen raises target price to $224 from $200

Aya Gold & Silver’s updated Boumadine study pegs after-tax NPV at $3.5 billion

Runway Growth Finance raised to buy from hold; target price cut to $7.5 from $10